

Date: 18-05-2023

To, The General manager, DCS-CRD, BSE Limited, Mumbai-400001

Sir,

SUB: Claiming exemption U/R. 15 (2) of SEBI (LODR) regulations 2015 for the FY 2023-24-reg

The company has undergone reduction of Equity share capital of the company vide NCLT order No. CA 52/66/HDB/2021 dated 06-01-2023. Due to this the company's Paid-up capital has reduced to Rs. 2,05,01,600/- from Rs. 10,25,08,000/-.

As per the Regulation 15(2) we confirm that;

- (1) The paid-up equity share capital not exceeds Rs. 10.00 crore; and
- (2) The net-worth is also not exceeding Rs. 25.00 crore as on the last day of the previous financial year

Therefore the Company is not liable to make compliances under regulations 17,17A, 18, 19, 20 21,22, 23, 24,24A, 25,26, 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 and para C D and E of Schedule V.

Therefore we hereby claim exemptions from the aforesaid regulations 17 17A 18 19 20 21 22 23 24 24A 25 26 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 and para C D and E of Schedule V being a company covered under Regulation 15(2).

Keeping in view of the aforesaid provisions we want to claim exemption U/R 15(2) of SEBI (LODR) regulations 2015 from 01-04-2023 to 31-03-2024. (ie for FY 2023-24).

This is for information and records of exchange, Thanking you,

For Hindustan Bio Sciences Limited

JVR Mohan Raju Managing Director

DIN No: 00060800

HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2, Banjara Hills, Hyderabad - 500 034, INDIA. +91 40 23555161 / 23555181 pharma.hindustanbio@gmail.com www.hindustan.bio CIN: L26942TG1991PLC013564